S'abonner

Component-resolved diagnostics study on nut sensitization and cross-reactivity in China - 22/10/25

Doi : 10.1016/j.rmed.2025.108365 
Wenting Luo a, 1, Xianhui Zheng a, 1, Jiale Zhang a, 1, Aoli Li a, 1, Jing Wu b, 1, Jinhai Ma c, 1, Yan Zhao d, 1, Xin Sun e, 1, Chunhua Wei f, 1, Huali Ren g, 1, Siqin Wang h, 1, Hong Zhang i, 1, Yun Sun j, 1, Guoping Li k, 1, Jianxin Sun l, 1, Dongming Huang m, 1, Ting Chen n, 1, Jinni Chen o, 1, Huashou Ke p, 1, Xiangping Ma q, 1, Bing Wan r, 1, Baoqing Sun a,
a Department of Allergy and Clinical Immunology, Department of Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China 
b Department of Allergy and Clinical Immunology, Inner Mongolia Cancer Hospital, Inner Mongolia, China 
c Ningxia Medical University General Hospital, Yinchuan, China 
d Department of Allergy, The First Affiliated Hospital, Harbin Medical University, Harbin, China 
e Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, China 
f Weifang Weien Hospital, Weifang, China 
g Department of Allergy, State Grid Beijing Electric Power Hospital, Capital Medical University Electric Power Teaching Hospital, Beijing, China 
h Henan Provincial People's Hospital, Zhengzhou, China 
i Department of Pediatrics, Gansu Provincial Hospital, Lanzhou, China 
j Department of Pediatrics, Yinchuan Maternal and Child Health Care Hospital, Yinchuan, China 
k Laboratory of Allergy and Precision Medicine, Department of Pulmonary and Critical Care Medicine, Chengdu Institute of Respiratory Health, Chengdu Third People's Hospital Branch of National Clinical Research Center for Respiratory Disease, Chengdu, China 
l The Second People's Hospital of Zhaoqing, China 
m Department of Pediatrics, Boai Hospital of Zhongshan City, Zhongshan, China 
n Shengli Clinical Medical College of Fujian Medical University, Department of Otorhinolaryngology Head and Neck Surgery, Fujian Provincial Hospital, Fuzhou, China 
o Hainan Maternal and Children's Medical Center, Haikou, China 
p Maoming Maternal and Child Health Hospital, Maoming, China 
q First Affiliated Hospital of Xinjiang Medical University, Urumqi, China 
r Department of Pulmonary and Critical Care Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China 

Corresponding author. Department of Allergy and Clinical Immunology, Department of Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiangxi Road, Guangzhou, Guangdong, 510120, China.Department of Allergy and Clinical ImmunologyDepartment of LaboratoryNational Center for Respiratory MedicineNational Clinical Research Center for Respiratory DiseaseState Key Laboratory of Respiratory DiseaseGuangzhou Institute of Respiratory Health First Affiliated Hospital of Guangzhou Medical University151 Yanjiangxi RoadGuangzhouGuangdong510120China

Abstract

Purpose

Nut sensitization in China remains insufficiently characterized. Component-resolved diagnosis (CRD) technology offers the ability to distinguish true food allergies from pollen-induced cross-sensitizations while avoiding the risks of oral food challenge (OFC) tests. This study aims to explore and validate the major allergenic components and patterns of cross-reactivity between nuts and pollens in patients with pollen-food allergy syndrome (PFAS).

Methods

This study evaluated the sensitization profiles of 104 patients with self-reported PFAS, focusing on crude extracts and major allergenic components of pollen and nuts. In addition, the presence of cross-reactive carbohydrate determinants (CCDs) was tested to determine if the specific immunoglobulin E (sIgE) detection of these plant allergens was influenced by non-specific reactions causing false positives. Furthermore, we conducted serum inhibition assays to explore the cross-reactivity between pollen and nut allergens.

Results

The majority of PFAS patients were from northern China, where sensitization to weed pollen, particularly mugwort, was more prevalent than to tree pollen or grass pollens. Hazelnut and walnut were identified as the most frequently sensitizing nut allergens, whereas sensitization rates to other nuts were markedly lower. CRD combined with serum inhibition assays demonstrated a common cross-sensitization between pollen and nut allergens. Notably, the hazelnut component Cor a 1-sIgE was significantly inhibited by birch pollen and its component Bet v 1, while Cor a 8-sIgE showed effective inhibition by mugwort pollen and its component Art v 3.

Conclusions

This is the first study to comprehensively evaluate nut sensitization and its key allergenic components in Chinese PFAS patients, confirming substantial cross-sensitization with pollen allergens. Specifically, birch and mugwort pollen significantly inhibited IgE binding to hazelnut. These findings provide component-resolved insights into the prevalence and mechanisms of nut allergies in China, enhancing our understanding of the allergenic landscape and informing clinical diagnosis and management strategies.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Image 1

Le texte complet de cet article est disponible en PDF.

Highlights

This study fills a knowledge gap regarding nut sensitization in Chinese patients with pollen-food allergy syndrome.
This study links exposure to mugwort and birch pollen with nut sensitization in clinical settings.
This study demonstrates cross-reactivity and the major components between pollen and nut allergens through component-resolved diagnostics.
This study supports tailored approaches for allergy diagnosis and management in regions with high pollen exposure.

Le texte complet de cet article est disponible en PDF.

Keywords : Pollen-food allergy syndrome, Nut sensitization, Component-resolved diagnosis, Cross-reactivity, Inhibition test


Plan


© 2025  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 248

Article 108365- novembre 2025 Retour au numéro
Article précédent Article précédent
  • Triangulation evidence for the causal effect of monocytes on pulmonary artery hypertension: a Mendelian randomization study and results from NHANES
  • Zhekang Liu, Qingan Fu, Yijia Shao, Junda Cao
| Article suivant Article suivant
  • Morpho-clinical insights into moderate-to-severe obstructive sleep apnea
  • Moussa Riachy, Sophie Riachy, Albert Riachy, Farid Mallat, Nicolas Medawar, Thalia Hanna, Kristy Braidy, Dalia Al Halabi, Joe Elio El Chaer, Karl Chammas, Antoine El Kik, Hind Eid

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.